Drug Profile
Research programme: liposomal HIV vaccine - Xenetic Biosciences
Latest Information Update: 27 Nov 2014
Price :
$50
*
At a glance
- Originator Lipoxen Technologies
- Developer Xenetic Biosciences
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections